See more : Zonte Metals Inc. (EREPF) Income Statement Analysis – Financial Results
Complete financial analysis of SCYNEXIS, Inc. (SCYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SCYNEXIS, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Taiwan Advance Bio-Pharmaceutical Inc. (4186.TWO) Income Statement Analysis – Financial Results
- RVH Inc. (6786.T) Income Statement Analysis – Financial Results
- Grand Vision Media Holdings Plc (GVMH.L) Income Statement Analysis – Financial Results
- Davangere Sugar Company Limite (DAVANGERE.BO) Income Statement Analysis – Financial Results
- Boundary Gold and Copper Mining Ltd. (PRZFF) Income Statement Analysis – Financial Results
SCYNEXIS, Inc. (SCYX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.scynexis.com
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140.14M | 5.09M | 13.16M | 0.00 | 121.00K | 257.00K | 257.00K | 257.00K | 257.00K | 1.26M | 16.86M | 16.84M |
| Cost of Revenue | 15.62M | 628.00K | 312.00K | 303.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.45M | 16.31M | 14.36M |
| Gross Profit | 124.52M | 4.46M | 12.85M | -303.00K | 121.00K | 257.00K | 257.00K | 257.00K | 257.00K | -14.19M | 552.00K | 2.47M |
| Gross Profit Ratio | 88.85% | 87.66% | 97.63% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -1,129.78% | 3.27% | 14.69% |
| Research & Development | 30.93M | 27.26M | 23.77M | 36.52M | 38.39M | 21.56M | 18.33M | 20.08M | 16.44M | 8.29M | 4.36M | 8.93M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.68M | 8.25M | 8.00M | 12.17M | 7.57M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.00K | 0.00 | 0.00 |
| SG&A | 20.92M | 62.96M | 49.92M | 14.63M | 10.65M | 8.68M | 8.25M | 8.00M | 12.17M | 7.62M | 4.38M | 4.74M |
| Other Expenses | 0.00 | 3.00K | -13.00K | -334.00K | 538.00K | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 4.38M | 12.00K |
| Operating Expenses | 51.85M | 90.22M | 73.68M | 50.82M | 49.04M | 30.24M | 26.58M | 28.07M | 28.61M | 15.90M | 8.74M | 13.67M |
| Cost & Expenses | 67.47M | 90.85M | 73.99M | 50.82M | 49.04M | 30.24M | 26.58M | 28.07M | 28.61M | 15.90M | 25.05M | 28.03M |
| Interest Income | 3.95M | 1.42M | 24.00K | 189.00K | 805.00K | 967.00K | 386.00K | 185.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.13M | 5.20M | 2.66M | 1.18M | 986.00K | 2.05M | 1.86M | 351.00K | 11.00K | 803.00K | 11.89M | 972.00K |
| Depreciation & Amortization | 810.00K | 813.00K | 577.00K | 303.00K | 285.00K | 53.00K | 41.00K | 26.00K | 447.00K | 1.24M | 1.33M | 1.49M |
| EBITDA | 73.48M | -59.91M | -31.41M | -51.15M | -51.27M | -17.10M | -23.16M | -29.51M | -27.90M | -2.19M | -13.76M | -9.71M |
| EBITDA Ratio | 52.43% | -1,675.94% | -468.93% | 0.00% | -40,196.69% | -11,269.65% | -10,075.10% | -10,780.54% | -10,856.81% | -1,128.50% | -61.39% | -74.91% |
| Operating Income | 72.67M | -85.76M | -60.83M | -51.15M | -48.92M | -29.98M | -26.32M | -27.82M | -28.35M | -14.65M | -7.20M | -7.78M |
| Operating Income Ratio | 51.85% | -1,684.48% | -462.09% | 0.00% | -40,430.58% | -11,666.54% | -10,241.25% | -10,823.74% | -11,030.74% | -1,166.16% | -42.74% | -46.23% |
| Total Other Income/Expenses | -5.49M | 18.25M | 24.88M | -7.18M | -4.79M | 10.78M | 1.26M | -2.17M | 11.00K | 7.88M | -23.26M | -281.00K |
| Income Before Tax | 67.18M | -67.51M | -35.95M | -58.33M | -53.71M | -19.20M | -25.06M | -29.99M | -28.34M | -6.77M | -30.46M | -11.48M |
| Income Before Tax Ratio | 47.94% | -1,326.05% | -273.14% | 0.00% | -44,388.43% | -7,472.37% | -9,750.97% | -11,668.87% | -11,026.46% | -538.93% | -180.70% | -68.17% |
| Income Tax Expense | 138.00K | -4.70M | -3.09M | -3.15M | 1.52M | -6.74M | 1.86M | 351.00K | -4.29M | -1.17M | 11.89M | 984.00K |
| Net Income | 67.04M | -62.81M | -32.87M | -55.19M | -55.23M | -12.47M | -25.06M | -29.99M | -32.62M | -4.23M | -30.46M | -11.48M |
| Net Income Ratio | 47.84% | -1,233.73% | -249.68% | 0.00% | -45,647.93% | -4,851.36% | -9,750.97% | -11,668.87% | -12,693.77% | -337.10% | -180.70% | -68.17% |
| EPS | 1.40 | -1.47 | -1.25 | -5.15 | -9.85 | -2.84 | -9.37 | -15.75 | -26.82 | -7.48 | -192.64 | -72.58 |
| EPS Diluted | 1.39 | -1.47 | -1.25 | -5.15 | -9.85 | -2.84 | -9.37 | -15.75 | -26.82 | -7.13 | -192.64 | -72.58 |
| Weighted Avg Shares Out | 47.85M | 42.61M | 26.38M | 10.72M | 5.61M | 4.39M | 2.67M | 1.90M | 1.22M | 566.33K | 158.13K | 158.13K |
| Weighted Avg Shares Out (Dil) | 48.39M | 42.61M | 26.38M | 10.72M | 5.61M | 4.39M | 2.67M | 1.90M | 1.22M | 593.71K | 158.13K | 158.13K |
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
BENSALEM, Pa. , Dec. 20, 2023 /PRNewswire/ -- Law Offices of Howard G.
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX) for violations of §§10(b) and...
Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'
Scynexis is developing a novel antifungal category called "fungerps" to address antifungal resistance. The company's approved product, ibrexafungerp, has been licensed to GSK with anticipated peak sales of over $500M. Ibrexafungerp commercialization and clinical development was paused due to manufacturing...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX) for violations of §§10(b) and...
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
LOS ANGELES , Dec. 15, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against SCYNEXIS, Inc. ("Scynexis" or the "Company") (NASDAQ: SCYX). Class...
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX) for violations of 10(b) and...
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
LOS ANGELES , Dec. 13, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against SCYNEXIS, Inc. ("Scynexis" or the "Company") (NASDAQ: SCYX).
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX) for violations of 10(b) and...
ROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
NEW YORK , Dec. 12, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September 22, 2023, both dates inclusive (the "Class Period"),...
Source: https://incomestatements.info
Category: Stock Reports